KRN 633

貨號 Cat. No.
S1557
規格 Size
5~200mg
品牌 Brand
Selleckchem

Description


KRN 633
Catalog No.S1557

KRN 633 is an ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 170 nM/160 nM/125 nM, weakly inhibits PDGFR-α/β and c-Kit, does not block the phosphorylation of FGFR-1, EGFR or c-Met in cell.


















Size Price Stock Quantity  


































10mM/1mLIn DMSO USD 352 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
5mg USD 214 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
10mg USD 403 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
50mg USD 1222 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
200mg USD 3112 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 




 Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw


Biological Activity







































Description KRN 633 is an ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 170 nM/160 nM/125 nM, weakly inhibits PDGFR-α/β and c-Kit, does not block the phosphorylation of FGFR-1, EGFR or c-Met in cell.
Targets VEGFR1 VEGFR2 VEGFR3      
IC50 170 nM 160 nM 125 nM [1]      
In vitro KRN 633, a novel quinazoline urea derivative, strongly inhibits VEGFR1, VEGFR2 and VEGFR3 receptors with IC50 values of 170 nM, 160 nM and 125 nM respectively. It shows lower inhibitory activity towards non-RTKs, such as PDGF receptor (PDGFRα and β, c-Kit, breast tumor kinase, and tunica interna endothelial cell kinase tyrosine kinases (IC50 = 965, 9850, 4330, 9200, and 9900 nM, respectively). KRN 633 potently inhibits ligand VEGF induced phosphorylation of VEGFR2 in HUVECs with an IC50 of 1.16 nM. KRN 633 also inhibits VEGF-dependent, but not bFGF-dependent, phosphorylation of the MAP kinases in endothelial cells, with IC50 values of 3.51 nM and 6.08 nM for ERK1 and ERK2, respectively. KRN633 has also been shown to inhibit the VEGF-driven proliferation of HUVECs with an IC50 of 14.9 nM, but it only suppresses FGF-driven proliferation at 3 μM weakly. [1] KRN 633 inhibits hypoxia-induced transcriptional activation of HIF-1α in a concentration-dependent manner with an IC50 of 3.79 μM, through the inhibition of both Akt and ERK phosphorylation signaling pathways. [2]
In vivo Although not cytotoxic to various cancer cells in vitro, KRN633 exhibits excellent antitumor activity in vivo due to its inhibitory effect on tumor vessel formation and vascular permeability. Once-daily administration of KRN633 at 100 mg/kg/d produces significant tumor growth inhibition in A549, LC-6-LCK, HT29, Ls174T, LNCap and Du145 cells while twice-daily administration of KRN633 at 100 mg/kg induces ~90% growth inhibition of HT29 tumors. [1] Treatment of mid-pregnancy mice with KRN 633 (300 mg/kg, p.o.) reduces the blood supply to fetal tissues due to diminished vascularization in both placenta and fetal organs and consequently increases the risk of induction of intrauterine growth restriction (IUGR). [3]
Features  

Protocol(Only for Reference)


Kinase Assay: [1]









Cell-Free Kinase Assays Cell-free kinase assays are done to obtain IC50 values against a variety of recombinant VEGF receptors. KRN633 is tested at concentrations varying from 0.3 nM to 10 μM. All assays are done in quadruplicate with 1 μM ATP.

Cell Assay: [1]





















Cell lines A549, Ls174T, DU145, HT29, LNCap and PC-3 cell lines
Concentrations Dissolved in DMSO, final concentrations 0.01 to 10 μM
Incubation Time 96 hours
Method Cancer cells are plated in media containig 10% FBS and antibiotics, at densities known to permit exponential growth over the assay period. The cells are cultured for 24 hours before adding KRN633 (0.01 to 10 μM) or just the vehicle (0.1% DMSO in medium) and then grown for a further 96 hours. Cell viability is measured using WST-1 reagent.

Animal Study: [1]





















Animal Models A549, Ls174T, HT29, DU145, LNCap, PC-3 cells and LC-6-JCK are established in athymic mice (BALB/cA, Jcl-nu) and athymic rats (F344/N, Jcl-rnu), respectively.
Dosages 20-100 mg/kg
Administration Gavage once daily
Solubility 0.5% methylcellulose/0.2% Tween 80 10 mg/mL

1


References


Chemical Information


Download KRN 633 SDF


 

















Molecular Weight (MW) 416.86
Formula

C20H21ClN4O4


CAS No. 286370-15-8















Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A

 


























Solubility (25°C) * In vitro DMSO 9 mg/mL (21 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.


 








Chemical Name 1-(2-chloro-4-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-propylurea

 

Preparing Stock Solutions



















Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.41686 4.1686 8.3372 -


 


 


 


 


 


 

詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢